Apixaban Intermedia CAS 545445-44-1 Puritas >98.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica 3-Morpholino-1-(4-(2-Oxopiperidin-1-yl) phenyl)-5,6-Dihydropyridin-2(1H)-una (CAS: 545445 -44-1) cum qualitate media Apixaban (CAS: 503612-47-3).Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase Apixaban media,Please contact: alvin@ruifuchem.com
| Nomen chemicum | 3-Morpholino-1-(4-(2-Oxopiperidin-1-yl) phenyl)-5,6-Dihydropyridin-2(1H)-one |
| Synonyma | Apixaban Intermediate 1;5,6-Dihydro-3-(4-Morpholinyl) -1-[4-(2-Oxo-1-Piperidinyl)phenyl]-2(1H)-Pyridinone;5-Morpholin-4-yl-1-[4-(2-Oxopiperidin-1-yl)phenyl]-2,3-Dihydropyridin-6-unum;Apixaban Impurity A |
| Stock Status | In Stock, Commercial Productio |
| CAS Number | 545445-44-1 |
| Formulae hypotheticae | C20H25N3O3 |
| M. Pondus | 355.43 g/mol |
| Liquescens punctum | >199℃(dec.) |
| Density | 1.267 g/mL |
| COA & MSDS | Praesto |
| Origin | Shanghai, China |
| Categoria | Apixaban (CAS: 503612-47-3) |
| Brand | Ruifu Chemical |
| Items | Specifications | Proventus |
| Aspectus | Lumen Yellow Pulvis | Lumen Yellow Pulvis |
| Damnum in Siccatio | <0.50% | 0.16% |
| Residere in Ignition | <0.20% | 0.07% |
| Puritas / Analysis Methodus | >98.0% (HPLC Area) | 99.12% |
| Omnis immunditia | <0.50% | <0.50% |
| Totalis immunditias | <2.00% | 0.88% |
| 1H NMR Imaginum | Congruunt Structure | Conforms |
| LC-MS pro Lepidium sativum | Conforms | Conforms |
| conclusio | Productum probatum est et cum datis specificationibus obsequitur | |
| Applicationem | Apixaban (CAS: 503612-47-3) | |
Sarcina:Fluorinated Utrem, aluminium ffoyle, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Continentem arcte clausam et in frigido, sicco et bene ventilato horreis a substantiis incompossibilibus repone.A luce et humore protege.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.
Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.
Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.
Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.
Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.
Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.
Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.
MOQ?Nec MOQ.Parvus ordo placet.
Tempus adferendi? Si intus prosapia, tres dies partus praestatur.
Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.
Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.
Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.
Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
3-Morpholino-1-(4-(2-Oxopiperidin-1-yl)phenyl)-5,6-Dihydropyridin-2(1H)-unum (CAS: 545445-44-1) medium est Apixaban (CAS: 503612-47-3).
Apixaban novum genus oralis Xa factoris inhibitoris oralis coniunctim a Bristol-Myers Squibb et Pfizer evolvit.Nomen artis Eratol, quod novum genus anticoagulantis oris est.Inhibendo factorem coagulationis magni Xa, Apixaban productionem et thrombosis thrombin impedire potest.Die XXVI mensis Aprilis anno MMVII, Bristol-Myers Squibb manus cum Pfizer coniunxit, ut nuntiaret cooperationem in evolutione novi oris anticoagulantis Apixaban, cui a Bristol-Myers Squibb alterutrius upgraded ad Warfarin fuerat.Mense Maio 2011, Apixaban primus probavit ne thrombosis venarum in adultis aegris coxam vel genu substitutionem chirurgiae electivae subeundae in 27 terris Europaeis, Islandia et Norvegia.Die XX mensis Novembris anno MMXII, Commissio Europaea Ererto (Apixaban) probata est, ne ictuum et embolismi systemici in adultis aegris cum fibrillatione atriali non-valvulare (NVAF) una vel pluribus periculum compleret.Postmodum Canadian Cibus et medicamentis Administrationis, Iaponiae et FDA US comprobavit Ererto (Apixaban) ad praeventioni ictum et systemicum embolismum in adultis aegris cum fibrillatione atriali non-valvulare (NVAF) una vel pluribus periculo factis.Die 12 Aprilis 2013, novum medicamentum anticoagulantis Eloto (ELIQUIS) (Apixaban) coniunctim elaboratum est a Bristol-Myers Squibb et Pfizer publice nuntiatum esse in Sinis recensendum.
![Apixaban Intermedia CAS 27143-07-3 Ethyl Chloro [(4-Methoxyphenyl)hydrazono]acetate puritatis ≥99.0% (HPLC)](https://www.ruifuchemical.com/uploads/Apixaban-Intermediate-CAS-490-46-0-Factory-Shanghai-Ruifu-Chemical-Co.-Ltd.-www.ruifuchem.com_-300x300.jpg)
